Safety and efficacy of AK0529 in respiratory syncytial virus‐infected infant patients: A phase 2 proof‐of‐concept trial

BACKGROUND: Respiratory syncytial virus (RSV) infection is a cause of substantial morbidity and mortality in young children. There is currently no effective therapy available. METHODS: This was a Phase 2 study of the oral RSV fusion protein inhibitor AK0529 in infants aged 1–24 months, hospitalized...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Li‐Min, Schibler, Andreas, Huang, Yi‐Chuan, Tai, Andrew, Chi, Hsin, Chieng, Chae‐Hee, Wang, Jinn‐Li, Goldbart, Aviv, Tang, Swee‐Ping, Huang, Yhu‐Chering, George, Shane, Alabaz, Derya, Bentur, Lea, Su, Siew‐Choo, de Bruyne, Jessie, Karadag, Bulent, Gu, Feng, Zou, Gang, Toovey, Stephen, DeVincenzo, John P., Wu, Jim Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368966/
https://www.ncbi.nlm.nih.gov/pubmed/37502622
http://dx.doi.org/10.1111/irv.13176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368966/
https://www.ncbi.nlm.nih.gov/pubmed/37502622
http://dx.doi.org/10.1111/irv.13176

Ejemplares similares